AstraZeneca PLC (AZN)vsOlink Holding AB ADR (OLK)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
OLK
Olink Holding AB ADR
$26.08
0.00%
HEALTHCARE · Cap: $3.24B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 35809% more annual revenue ($61.37B vs $170.89M). AZN leads profitability with a 17.0% profit margin vs -19.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
OLK
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-49.5%
Fair Value
$17.45
Current Price
$26.08
$8.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
4.7% revenue growth
0.0% earnings growth
Weak financial health signals
ROE of -7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : OLK
The strongest argument for OLK centers on Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : OLK
The primary concerns for OLK are Revenue Growth, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while OLK is a turnaround play — different risk/reward profiles.
OLK carries more volatility with a beta of 0.52 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 19/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Olink Holding AB ADR
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology and other institutions focused on life science research. The company is headquartered in Uppsala, Sweden.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?